Investment Services
Finance
Biotechnology

PDL BioPharma

$2.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.67%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PDL BioPharma and other stocks, options, ETFs, and crypto commission-free!

About

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. Read More The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.

Employees
105
Headquarters
Incline Village, Nevada
Founded
1986
Market Cap
365.31M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.53M
High Today
$3.03
Low Today
$2.92
Open Price
$3.00
Volume
614.77K
52 Week High
$3.89
52 Week Low
$2.25

Collections

Investment Services
Finance
Biotechnology
Biopharmaceutical
Pharmaceutical
Health

News

Yahoo FinanceMay 12

Were Hedge Funds Right About Piling Into PDL BioPharma Inc.?

How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of capital and have to conduct due diligence while choosing their next pick. They don't always get it right, but, on average, their stock picks historically generated strong returns after...

304
Seeking AlphaMay 9

PDL BioPharma beats by $0.01, beats on revenue

PDL BioPharma (NASDAQ:PDLI): Q1 Non-GAAP EPS of $0.09 beats by $0.01 ; GAAP EPS of $0.05 misses by $0.03 . Revenue of $38.9M (+1.0% Y/Y) beats by $4.22M . Press Release...

169
NasdaqMay 2

PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?

Investor focus will be on PDL BioPharma, Inc.'s PDLI ability to acquire new income-generating assets for a recurrent revenue uptick, when the company reports first-quarter 2019 earnings in the days ahead. The company's surprise track record has been impressive so far, having delivered an earnings beat in each of the trailing four quarters, the average being 38.39%. In the las t report ed quarter, PDL BioPharma came up with a positive surprise of 25.00%. Shares of PDL BioPharma have gained10.3% so far this...

224

Earnings

$0.01
$0.06
$0.11
$0.16
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.